Retatrutide Drug Information

Retatrutide - Overview

Retatrutide medication is a drug that is under investigated for weight loss. Retatrutide medication is not approved by the FDA and is not available in the US market at this time.

What Is Retatrutide Used For?

Retatrutide medication, sometimes referred to as LY3437943, is an investigational drug. Retatrutide medication belongs to a new class of medications that combine glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 (GLP-1) and glucagon. Data from one pre-clinical study also suggests that retatrutide medication might reduce cancer progression. Other studies are looking at how retatrutide medication might impact cardiovascular outcomes in patients with type 2 diabetes as well as metabolic dysfunction-associated steatotic liver disease.

Retatrutide - Dosage and Cost

Retatrutide medication demonstrates pharmacokinetics which are dose proportional. With a mean half-life of approximately 6 days, retatrutide prescription medication will likely be suitable for weekly dosing. Dosage and cost information for the retatrutide prescription drug candidate is not available at this time.

Retatrutide And Weight Loss

Retatrutide medication, similar to orforglipron, is under investigation for use in weight loss. Retatrutide targets GLP-1 receptors and two other hormones known as glucagon and glucose-dependent insulinotropic polypeptide (GIP). Due to these actions, retatrutide is sometimes referred to as a triple agonist or triple G (GGG) drug. It is likely that retatrutide medication will be a once-weekly injection similar to semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

Retatrutide has been studied in several Phase 3 trials as part of Eli Lilly's TRIUMPH clinical program. In one phase 2 trial, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. Another study also found that once-weekly retatrutide medication use was associated with a significant reduction in body weight.

Can I Buy Retatrutide Online?

Retatrutide is not yet approved by the FDA and remains an investigational medication in the United States. It is legally available only to participants enrolled in Eli Lilly's clinical trials. It is not recommended that anyone attempt to buy retatrutide online, as products marketed as retatrutide outside of clinical trials are not regulated and have not been verified for safety or authenticity.

Based on the current Phase 3 timeline and the typical FDA review process of 12 months following an NDA submission, retatrutide medication could potentially be available to the public as early as 2027 or 2028, assuming the remaining TRIUMPH trials are successful and the regulatory process proceeds on schedule. Patients interested in weight loss medication options today can connect with a medical provider through Push Health who can evaluate their situation and prescribe currently available options, including Mounjaro, Ozempic, Wegovy, and Zepbound, when appropriate to do so.

Retatrutide - Side Effects

Retatrutide medication can cause side effects when used but, to date, is generally well tolerated and comparable to control groups. Retatrutide may cause adverse reactions such as an increased heart rate and tingling of the skin with the most common side effect generally reported as being gastrointestinal.

More Retatrutide Information

• Retatrutide - NEJM